Trials / Completed
CompletedNCT03507569
Open Label, Adaptive, Parallel Group PET Study Using RO7017773 And [11C] RO15-4513
A Non-Randomized Open Label, Adaptive, Parallel Group, Human Positron Emission Tomography (PET) Study to Assess Occupancy of Brain alpha5-Containing GABAA Receptors of Ro7017773 Using [11C] Ro15-4513 Following Single Oral Doses in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 23 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is a single dose (SD), non-randomized, open-label, adaptive, parallel group study with the purpose of investigating the occupancy of alpha5-containing GABAA receptors by RO7017773 in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RO7017773 | RO7017773 will be administered orally. The doses to be tested will be determined by review of PET scan, PK, and safety results from the previous dose level. |
| OTHER | [11C] Ro15-4513 | At the start of each PET scan, participants will receive an intravenous dose of the radiolabeled tracer \[11C\]Ro15-4513. |
Timeline
- Start date
- 2018-04-24
- Primary completion
- 2018-06-22
- Completion
- 2018-06-22
- First posted
- 2018-04-25
- Last updated
- 2019-09-30
- Results posted
- 2019-09-30
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03507569. Inclusion in this directory is not an endorsement.